Kaleido Scope

Phase 1: Define the Future

Phase 1: Define the Future promotes a collective understanding and approach on the overall engagement. Phase 1 included an extensive data collection process and gathering insights from stakeholders ...
Nasdaq

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

SOUTH SAN FRANCISCO, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize ...
POWER Magazine

EPA Rolls Out Label Program to Define ‘Clean’ Construction

The Environmental Protection Agency (EPA) has announced a plan to implement a new label program that it expects will help federal purchasers and buyers find and choose more climate-friendly ...
Nasdaq

Alumis Inc. Completes Patient Enrollment for Phase 3 ONWARD Clinical Program Evaluating ESK-001 in Moderate-to-Severe Plaque Psoriasis

Alumis Inc. has announced the successful completion of patient enrollment in its pivotal Phase 3 ONWARD clinical program for ESK-001, a treatment for moderate-to-severe plaque psoriasis, involving ...